Drugs online research references
Neuropharmacology. 1995 Jan;34(1):89-96.
Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration.
Auerbach SB, Lundberg JF, Hjorth S.
Department of Biological Sciences, Nelson Biological Laboratories, Rutgers University, Piscataway, NJ, USA.
The inhibition of serotonin (5-HT) release produced by antidepressants varying in relative selectivity for blocking uptake of 5-HT and noradrenaline (NA) was compared. Release was measured by microdialysis in anesthetized rats with nerve terminal 5-HT uptake inhibited by local infusion of citalopram (1 microM) through a dialysis probe in hippocampus. With 5-HT uptake first blocked in hippocampus, systemic injection of uptake inhibitors produced decreases in dialysate 5-HT, presumably due to autoreceptor stimulation in the raphe. The largest decreases (about 60-70%) in 5-HT were produced by the selective 5-HT uptake inhibitors sertraline, paroxetine and citalopram. Nonselective blockers caused less suppression of release. Thus, the maximum decrease in 5-HT was 35% after clomipramine, a less selective 5-HT uptake inhibitor, and < or = 30% after the nonselective 5-HT/NA uptake blockers imipramine and amitriptyline, 5-HT was not decreased after maprotiline, a selective NA uptake blocker. Pretreatment with (+)WAY100135 to block 5-HT1A autoreceptors, abolished the inhibition of 5-HT release produced by systemic sertraline, clomipramine and imipramine. One explanation for the difference between selective and nonselective inhibitors with respect to central 5-HT release, is the excitatory effect of (alpha 1) adrenergic receptor stimulation on 5-HT neuronal discharge. However, pretreatment with alpha-methyl-p-tyrosine to deplete NA, did not influence the inhibition of 5-HT release produced by imipramine.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7623967&dopt=Abstract
word match zoloft online literature
Alcohol. 1995 May-Jun;12(3):177-81.
Selective serotonin reuptake inhibitors: effects of chronic treatment on ethanol-reinforced behavior in mice.
Gulley JM, McNamara C, Barbera TJ, Ritz MC, George FR.
Southwest Institute for Drug and Alcohol Studies, Albuquerque, NM 87190-3991, USA.
Several lines of evidence suggest that aspects of ethanol drinking are mediated, at least in part, by serotonergic (5-HT) neurotransmitter systems. Ethanol-preferring animals show decreases in serotonin function and receptor densities. In addition, serotonin uptake inhibitors have been shown to decrease ethanol consumption in animal models and in humans. However, the time course of these effects and their duration remain undetermined. In the present studies, C57BL/6J male mice were treated with one of three selective 5-HT reuptake inhibitors (SSRIs): fluoxetine, sertraline, or paroxetine. All three drugs produced initial decreases in operant lever pressing behavior for ethanol followed by a return to baseline on subsequent days. Immediately following 14 days of this initial treatment, subsequent treatment with higher SSRI doses was ineffective in decreasing ethanol-reinforced behavior. However, after a several week "washout period," SSRI pretreatment again produced an initial decrease in responding for ethanol, again followed by a return to baseline. Thus, suppression of ethanol drinking may be related to immediate changes in 5-HT function following treatment with SSRIs, and tolerance to this effect appears to develop rapidly.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7639947&dopt=Abstract
word match zoloft online literature
utmb.edu
OBJECTIVE: To compare depression-related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline, paroxetine, or fluoxetine. PATIENTS AND METHODS: Claims records from a national database of patients diagnosed with depression who began treatment with an SSRI in 1995, following an antidepressant medication-free period of at least 6 months, were included. Treatment course and associated depression-related treatment and total healthcare costs during the subsequent 12-month treatment period were examined using univariate and multivariate methods. RESULTS: Nine-hundred five (905) patients taking sertraline, 492 on paroxetine, and 945 on fluoxetine met inclusion criteria. The groups were similar and representative with respect to gender and age. Mean dose over the 12-month treatment period increased 24%, indicating significant titration in all cohorts. Patients treated with paroxetine had shorter treatment duration (157.0 days) than did patients treated with fluoxetine (192.6 days) or sertraline (166.9 days, P < 0.001). Patients receiving index treatment with paroxetine were most likely to switch to another SSRI (21.3%); those taking sertraline were second most likely to switch (16.1%); and those on fluoxetine were least likely (12.4%, P = 0.001). Mean costs for depression-related outpatient visits and hospitalizations were similar. Mean antidepressant prescription costs differed, being $586, $419, and $446 for fluoxetine, paroxetine and sertraline cohorts, respectively (P < 0.001). In this sample, the fluoxetine cohort did not have lower nonpharmaceutical healthcare costs to offset higher pharmaceutical acquisition costs. Conclusions from median and multivariate analyses were robust to these findings. CONCLUSIONS: During this study period when fluoxetine, paroxetine, and sertraline were all well-established agents, similar depression-related treatment courses and cost characteristics among all 3 drugs were observed.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10537866&dopt=Abstract
word match zoloft online literature
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||